<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04169269</url>
  </required_header>
  <id_info>
    <org_study_id>20192684</org_study_id>
    <nct_id>NCT04169269</nct_id>
  </id_info>
  <brief_title>Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban</brief_title>
  <official_title>Patient Adherence to Venous Thromboembolism Prophylaxis in Orthopaedic Trauma Patients: A Randomized, Controlled Trial Comparing Subcutaneous Enoxaparin &amp; Oral Rivaroxaban</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Florida Orthopaedic Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orthopaedic Trauma Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Florida Orthopaedic Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare oral rivaroxaban with injectable enoxaparin in
      orthopaedic trauma patients to determine if orally administered rivaroxaban once daily
      carries greater compliance and overall satisfaction than enoxaparin self-administered by
      subcutaneous injection once daily.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, controlled trial of orthopaedic trauma patients presenting to a
      single academic level one trauma center that require an extended course of venous
      thromboembolism event chemoprophylaxis. The goal is to compare oral rivaroxaban with our
      standard-of-care, injectable enoxaparin in orthopaedic trauma patients to determine if orally
      administered rivaroxaban once daily carries greater compliance and overall satisfaction than
      enoxaparin self-administered by subcutaneous injection once daily.

      All patients included in the study would be treated with the standard enoxaparin 40 milligram
      injection while an inpatient. Upon hospital discharge, those requiring extended venous
      thromboembolism event chemoprophylaxis will be randomized to receive 20 days of either
      self-injected enoxaparin 40 milligrams or oral rivaroxaban,10 milligrams, a non-vitamin K
      oral anticoagulant. Both groups will then receive our current standard of care, aspirin 81
      milligrams once daily for the remaining 3 weeks, for a total of 6 weeks of venous
      thromboembolism event chemoprophylaxis. Routine postoperative care will be provided by the
      treating surgeon.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants are randomized to one of two medications.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>adherence to medication regimen</measure>
    <time_frame>2 weeks</time_frame>
    <description>measured with Morisky Medication Adherence Scale instrument; Score range is 0-8, 0 = low adherence to medication regimen, 8 = jigh adherence to medication regimen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>adherence to medication regimen</measure>
    <time_frame>6 weeks</time_frame>
    <description>measured with Morisky Medication Adherence Scale instrument; Score range is 0-8, 0 = low adherence to medication regimen, 8 = jigh adherence to medication regimen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>patient satisfaction with treatment regimen</measure>
    <time_frame>2 weeks</time_frame>
    <description>measured with Treatment Satisfaction Questionnaire for Medication (TSQM-9) instrument. TSQM-9 scores have a range of 0 to 100, with higher scores indicating higher satisfaction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>patient satisfaction with treatment regimen</measure>
    <time_frame>6 weeks</time_frame>
    <description>measured with Treatment Satisfaction Questionnaire for Medication (TSQM-9) instrument. TSQM-9 scores have a range of 0 to 100, with higher scores indicating higher satisfaction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a bleeding event</measure>
    <time_frame>2 weeks</time_frame>
    <description>measured through record review and participant reporting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a bleeding event</measure>
    <time_frame>6 weeks</time_frame>
    <description>measured through record review and participant reporting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a bleeding event</measure>
    <time_frame>3 months</time_frame>
    <description>measured through record review and participant reporting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a clotting event</measure>
    <time_frame>2 weeks</time_frame>
    <description>measured through record review and participant reporting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a clotting event</measure>
    <time_frame>6 weeks</time_frame>
    <description>measured through record review and participant reporting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a clotting event</measure>
    <time_frame>3 months weeks</time_frame>
    <description>measured through record review and participant reporting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment cost</measure>
    <time_frame>3 months</time_frame>
    <description>cost in U.S. dollars for 20 days of treatment drug</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Deep Vein Thrombosis</condition>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Enoxaparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>enoxaparin injectable, 40 milligram subcutaneous injection daily for 20 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rivaroxaban oral 10 milligram tablet daily for 20 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin 40 milligram/0.4 milliliter Injectable Syringe 0.4 milliliters</intervention_name>
    <description>anticoagulant, subcutaneous injection</description>
    <arm_group_label>Enoxaparin</arm_group_label>
    <other_name>Lovenox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban 10 milligram Oral Tablet</intervention_name>
    <description>anticoagulant, oral</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Orthopaedic trauma patients deemed by the attending, treating surgeon to require an
             extended duration of venous thromboembolism chemoprophylaxis beyond that provided as
             an inpatient.

               -  Patients being discharged directly to home.

        Exclusion Criteria:

          -  • Patients being discharged to a rehabilitation center or a skilled nursing facility.

               -  A contraindication to anticoagulation such as traumatic or other hemorrhage, as
                  determined by the treating surgeon and/or consulting services.

               -  Ongoing venous thromboembolism treatment or extended prophylaxis (i.e. past
                  history of multiple deep vein thrombosis/pulmonary embolism) for current or
                  recent deep vein thrombosis, pulmonary embolism or other coagulopathic disorder

               -  Chronic anticoagulation for atrial fibrillation or other medical disorder
                  requiring chronic anticoagulation therapy.

               -  Perceived low-risk patients requiring only aspirin or no pharmacological venous
                  thromboembolism prophylaxis.

               -  Pregnant, prisoner, under 18 years old, or do not speak English
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hassan Mir, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida Orthopaedic Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Steverson, MHA</last_name>
    <phone>8132532068</phone>
    <email>bsteverson@floridaortho.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Randi Alexander, MPH</last_name>
    <phone>8132532068</phone>
    <email>bsteverson@floridaortho.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Florida Orthopaedic Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Steverson, MHA</last_name>
      <phone>813-253-2068</phone>
      <email>bsteverson@floridaortho.com</email>
    </contact>
    <contact_backup>
      <last_name>Randi Alexander, MPH</last_name>
      <phone>8132532068</phone>
      <email>ralexander@floridaortho.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hassan Mir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 15, 2019</study_first_submitted>
  <study_first_submitted_qc>November 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2019</study_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Florida Orthopaedic Institute</investigator_affiliation>
    <investigator_full_name>Barbara Steverson</investigator_full_name>
    <investigator_title>Director of Research, Orthopaedic Trauma Service</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

